Pharming Group (PHAR) Expected to Post Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Pharming Group to announce earnings of $0.0630 per share and revenue of $99.5160 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:30 AM ET.

Pharming Group (NASDAQ:PHAR) last announced its earnings results on Thursday, May 7th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.12). The firm had revenue of $72.45 million during the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. On average, analysts expect Pharming Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Pharming Group Trading Up 1.1%

NASDAQ PHAR opened at $12.76 on Tuesday. Pharming Group has a 52 week low of $9.54 and a 52 week high of $21.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.06 and a current ratio of 2.63. The stock’s 50 day moving average price is $13.13 and its two-hundred day moving average price is $15.36. The stock has a market capitalization of $902.80 million, a price-to-earnings ratio of 79.72 and a beta of -0.04.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group during the 2nd quarter worth approximately $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group during the fourth quarter worth $224,000. Millennium Management LLC bought a new stake in Pharming Group during the fourth quarter worth $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after acquiring an additional 28,615 shares in the last quarter. Institutional investors and hedge funds own 0.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on PHAR shares. Wall Street Zen downgraded shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings cut shares of Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a report on Monday, May 11th. Canaccord Genuity Group began coverage on shares of Pharming Group in a research report on Friday, April 10th. They issued a “buy” rating and a $37.00 target price for the company. Finally, Zacks Research upgraded shares of Pharming Group from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharming Group has an average rating of “Hold” and an average price target of $38.33.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.